Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Anticholesteremic Agents"" wg kryterium: Temat


Tytuł :
Effect of the acute and chronic administration of Lupinus albus β-conglutin on glycaemia, circulating cholesterol, and genes potentially involved.
Autorzy :
Guzmán TJ; Instituto de Investigación en Enfermedades Crónico-Degenerativas, Instituto Transdisciplinar de Investigación e Innovación en Salud, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jalisco, México. Electronic address: .
Martínez-Ayala AL; Centro de Desarrollo de Productos Bióticos, Instituto Politécnico Nacional. Yautepec, Morelos, México. Electronic address: .
García-López PM; Laboratorio de Productos Bióticos, Departamento de Botánica y Zoología, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara. Zapopan, Jalisco, México. Electronic address: .
Soto-Luna IC; Instituto de Investigación en Enfermedades Crónico-Degenerativas, Instituto Transdisciplinar de Investigación e Innovación en Salud, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jalisco, México. Electronic address: .
Gurrola-Díaz CM; Instituto de Investigación en Enfermedades Crónico-Degenerativas, Instituto Transdisciplinar de Investigación e Innovación en Salud, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jalisco, México. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jan; Vol. 133, pp. 110969. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Lupinus*/chemistry
Anticholesteremic Agents/*pharmacology
Blood Glucose/*drug effects
Cholesterol/*blood
Diabetes Mellitus, Experimental/*drug therapy
Hypoglycemic Agents/*pharmacology
Liver/*drug effects
Plant Extracts/*pharmacology
Plant Proteins/*pharmacology
Seed Storage Proteins/*pharmacology
Transcriptome/*drug effects
Animals ; Anticholesteremic Agents/isolation & purification ; Biomarkers/blood ; Blood Glucose/metabolism ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/chemically induced ; Diabetes Mellitus, Experimental/genetics ; Gene Regulatory Networks ; Hypoglycemic Agents/isolation & purification ; Liver/metabolism ; Male ; Plant Extracts/isolation & purification ; Plant Proteins/isolation & purification ; Rats, Wistar ; Streptozocin
Czasopismo naukowe
Tytuł :
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Autorzy :
Yusuf S; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Joseph P; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Dans A; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Gao P; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Teo K; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Xavier D; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
López-Jaramillo P; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Yusoff K; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Santoso A; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Gamra H; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Talukder S; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Christou C; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Girish P; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Yeates K; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Xavier F; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Dagenais G; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Rocha C; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
McCready T; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Tyrwhitt J; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Bosch J; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Pais P; From the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON (S.Y., P.J., P. Gao, K.T., C.C., T.M., J.T., J.B.), Queen's University, Kingston, ON (K. Yeates), and Université Laval Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (G.D.) - all in Canada; the University of the Philippines, Manila (A.D.); St. John's Medical College, Bangalore, India (D.X., P. Girish, F.X., P.P.); Fundación Oftalmológica de Santander, Universidad de Santander, Bucaramanga, Colombia (P.L.-J., C.R.); Universiti Teknologi MARA Selayang, Selangor, and UCSI University, Cheras, Kuala Lumpur - both in Malaysia (K. Yusoff); Universitas Indonesia, National Cardiovascular Center, Jakarta (A.S.); Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia (H.G.); and Eminence, Dhaka, Bangladesh (S.T.).
Pokaż więcej
Corporate Authors :
International Polycap Study 3 Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jan 21; Vol. 384 (3), pp. 216-228. Date of Electronic Publication: 2020 Nov 13.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anticholesteremic Agents/*administration & dosage
Antihypertensive Agents/*administration & dosage
Aspirin/*therapeutic use
Cardiovascular Diseases/*prevention & control
Platelet Aggregation Inhibitors/*therapeutic use
Aged ; Anticholesteremic Agents/adverse effects ; Antihypertensive Agents/adverse effects ; Atenolol/administration & dosage ; Blood Pressure/drug effects ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/mortality ; Cholesterol, LDL/blood ; Drug Combinations ; Drug Therapy, Combination ; Female ; Humans ; Hydrochlorothiazide/administration & dosage ; Incidence ; Male ; Medication Adherence ; Middle Aged ; Risk Factors ; Simvastatin/administration & dosage
Czasopismo naukowe
Tytuł :
The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats.
Autorzy :
Takubo H; Drug Metabolism and Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan.
Ishikawa T; Drug Metabolism and Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan.
Taniguchi T; Drug Metabolism and Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan.
Iwanaga K; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan.
Nomura Y; Drug Metabolism and Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan.
Pokaż więcej
Źródło :
Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2021 Jan; Vol. 51 (1), pp. 82-87. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents/*pharmacokinetics
Sulfhydryl Compounds/*pharmacokinetics
Administration, Oral ; Animals ; Anticholesteremic Agents/administration & dosage ; Cholesterol Ester Transfer Proteins ; Humans ; Male ; Rats ; Sulfhydryl Compounds/administration & dosage
Czasopismo naukowe
Tytuł :
[UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020].
Autorzy :
Cohen H; The Bert W. Strassburger Lipid Center, The Chaim Sheba Medical Center, Tel-Hashomer , Israel.; Sackler Faculty of Medicine, Tel Aviv University, Israe.
Durst R; Cardiology, Center for Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Avizohar O; The Periodic Examinations Institute, Rambam Healthcare Campus, Haifa, Israel.
Elis A; Sackler Faculty of Medicine, Tel Aviv University, Israel.; Department of Internal Medicine, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Arbel Y; Sackler Faculty of Medicine, Tel Aviv University, Israel.; CardioVascular Research Center, Tel Aviv Sourasky Medical Center.
Bornstein N; Neurological Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Bachrach R; Clalit Health Services, Sharon-Shomron District, Israel.
Bareket R; Sackler Faculty of Medicine, Tel Aviv University, Israel.; Israeli Union of Family Physicians.
Gavish D; Cardivascular Research Center, Edith Wolfson Medical Center, Holon, Israel.; Cardiometabolic Clinic, Shaare Zedek Medical Center, Jerusalem, Israel.
Tanne D; Stroke and Cognition Institute Rambam Health Care Campus.; The Israel Neurological Association.
Lavon E; Israeli Association of Family Physicians.; Kaplan Medical Center, Clalit Health Services, Rehovot, Israel.
Zafrir B; Cardiovascular Department Lady Davis Carmel Medical Center, Haifa, Israel.
Kamari Y; The Bert W. Strassburger Lipid Center, The Chaim Sheba Medical Center, Tel-Hashomer.; Sackler Faculty of Medicine, Tel Aviv University, Israel.
Shechter M; Clinical Research Unit,Leviev Heart Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Israel.
Henkin Y; Ben-Gurion University, Beer-Sheva, Israel.; Preventive Cardiology Service, Department of Cardiology, Soroka University Medical Centre, Beer Sheva, Israel.
Pokaż więcej
Źródło :
Harefuah [Harefuah] 2021 Jan; Vol. 160 (1), pp. 38-44.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents*
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/prevention & control
Dyslipidemias*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Humans ; Israel ; Proprotein Convertase 9
Czasopismo naukowe
Tytuł :
Evinacumab in Patients with Refractory Hypercholesterolemia.
Autorzy :
Rosenson RS; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Burgess LJ; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Ebenbichler CF; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Baum SJ; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Stroes ESG; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Ali S; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Khilla N; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Hamlin R; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Pordy R; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Dong Y; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Son V; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Gaudet D; From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) - both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC - both in Canada (D.G.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Dec 10; Vol. 383 (24), pp. 2307-2319. Date of Electronic Publication: 2020 Nov 15.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiopoietin-like Proteins/*antagonists & inhibitors
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Anticholesteremic Agents/*therapeutic use
Hyperlipoproteinemia Type II/*drug therapy
Adult ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/adverse effects ; Cholesterol, LDL/blood ; Double-Blind Method ; Drug Administration Schedule ; Drug Resistance ; Female ; Humans ; Infusions, Intravenous ; Injections, Subcutaneous ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Preparation of phytosteryl ornithine ester hydrochloride and improvement of its bioaccessibility and cholesterol-reducing activity in vitro.
Autorzy :
Jia C; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; International Joint Laboratory on Food Safety, Jiangnan University, Wuxi 214122, China.
Xia X; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; International Joint Laboratory on Food Safety, Jiangnan University, Wuxi 214122, China. Electronic address: .
Wang H; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China.
Bertrand M; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; International Joint Laboratory on Food Safety, Jiangnan University, Wuxi 214122, China.
Chen G; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China.
Zhang X; State Key Laboratory of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; School of Food Science and Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, Jiangsu, China; International Joint Laboratory on Food Safety, Jiangnan University, Wuxi 214122, China.
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2020 Nov 30; Vol. 331, pp. 127200. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents/*chemistry
Acetates/chemistry ; Anticholesteremic Agents/chemical synthesis ; Anticholesteremic Agents/pharmacokinetics ; Biological Availability ; Cholesterol/metabolism ; Digestion ; Emulsifying Agents/chemistry ; Esterification ; Humans ; Hydrolysis ; Magnetic Resonance Spectroscopy ; Ornithine/chemistry ; Phytosterols/chemical synthesis ; Solubility ; Soybean Oil/chemistry ; Spectroscopy, Fourier Transform Infrared ; Water
Czasopismo naukowe
Tytuł :
The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.
Autorzy :
Murphy C; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Deplazes E; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Cranfield CG; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Garcia A; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 19; Vol. 21 (22). Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticholesteremic Agents/*therapeutic use
Cell Membrane/*drug effects
Cholesterol, LDL/*antagonists & inhibitors
Hydroxymethylglutaryl CoA Reductases/*chemistry
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Hypercholesterolemia/*drug therapy
Anticholesteremic Agents/chemical synthesis ; Anticholesteremic Agents/metabolism ; Biological Transport ; Biotransformation ; Cell Membrane/chemistry ; Cell Membrane/metabolism ; Cholesterol, LDL/biosynthesis ; Cholesterol, LDL/blood ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Hepatocytes/pathology ; Humans ; Hydrophobic and Hydrophilic Interactions ; Hydroxymethylglutaryl CoA Reductases/genetics ; Hydroxymethylglutaryl CoA Reductases/metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism ; Hypercholesterolemia/blood ; Hypercholesterolemia/genetics ; Hypercholesterolemia/pathology ; Lipid Bilayers/chemistry ; Lipid Bilayers/metabolism ; Liver/drug effects ; Liver/metabolism ; Liver/pathology ; Models, Molecular ; Protein Binding ; Protein Structure, Secondary ; Thermodynamics
Czasopismo naukowe
Tytuł :
Comparison of High-Dose Rosuvastatin Versus Low-Dose Rosuvastatin Plus Ezetimibe on Carotid Atherosclerotic Plaque Inflammation in Patients with Acute Coronary Syndrome.
Autorzy :
Oh M; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim H; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Shin EW; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sung C; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim DH; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Moon DH; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim N; Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Eo JS; Department of Nuclear Medicine, Korea University Guro Hospital, Seoul, South Korea.
Kim JW; Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
Lee CW; Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. .; Division of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea. .
Pokaż więcej
Źródło :
Journal of cardiovascular translational research [J Cardiovasc Transl Res] 2020 Dec; Vol. 13 (6), pp. 900-907. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Plaque, Atherosclerotic*
Acute Coronary Syndrome/*drug therapy
Anti-Inflammatory Agents/*administration & dosage
Anticholesteremic Agents/*administration & dosage
Carotid Artery Diseases/*drug therapy
Ezetimibe/*administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
Rosuvastatin Calcium/*administration & dosage
Acute Coronary Syndrome/diagnostic imaging ; Aged ; Anti-Inflammatory Agents/adverse effects ; Anticholesteremic Agents/adverse effects ; Carotid Artery Diseases/diagnostic imaging ; Drug Combinations ; Ezetimibe/adverse effects ; Female ; Fluorodeoxyglucose F18/administration & dosage ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Radiopharmaceuticals/administration & dosage ; Rosuvastatin Calcium/adverse effects ; Seoul ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Histamine and cholesterol lowering abilities of lactic acid bacteria isolated from artisanal Pico cheese.
Autorzy :
Domingos-Lopes MFP; Instituto de Investigação e Tecnologias Agrárias e do Ambiente dos Açores (IITAA), Universidade dos Açores, Angra do Heroísmo, Portugal.
Stanton C; Teagasc Moorepark Food Reseach Centre, Fermoy, Cork, Ireland.; APC Microbiome Institute, University College Cork, Cork, Ireland.
Ross RP; APC Microbiome Institute, University College Cork, Cork, Ireland.
Silva CCG; Instituto de Investigação e Tecnologias Agrárias e do Ambiente dos Açores (IITAA), Universidade dos Açores, Angra do Heroísmo, Portugal.
Pokaż więcej
Źródło :
Journal of applied microbiology [J Appl Microbiol] 2020 Dec; Vol. 129 (6), pp. 1428-1440. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents/*pharmacology
Cheese/*microbiology
Histamine Antagonists/*pharmacology
Lactobacillales/*physiology
Probiotics/*pharmacology
Animals ; Anticholesteremic Agents/isolation & purification ; Caco-2 Cells ; Histamine Antagonists/isolation & purification ; Humans ; Lactobacillales/isolation & purification ; Lactobacillus paracasei/isolation & purification ; Lactobacillus paracasei/physiology ; Milk/microbiology ; Probiotics/isolation & purification
Czasopismo naukowe
Tytuł :
Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk”.
Autorzy :
Češka R
Pokaż więcej
Transliterated Title :
Poznámky k novému „Doporučení pro léčbu dyslipid­emií. Ovlivnění lipidů ke snížení kardiovaskulárního rizika“.
Źródło :
Vnitrni lekarstvi [Vnitr Lek] 2020 Winter; Vol. 65 (12), pp. 755-760.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents*/therapeutic use
Cardiovascular Diseases*/prevention & control
Dyslipidemias*/complications
Dyslipidemias*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Ezetimibe ; Humans ; Lipids ; Proprotein Convertase 9 ; Risk Factors
Czasopismo naukowe
Tytuł :
Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
Autorzy :
Ingueneau C; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France. Electronic address: .
Hollstein T; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany; Division of Endocrinology, Diabetology and Clinical Nutrition, Department of Internal Medicine 1, University of Kiel, Arnold Heller Straße 3, Kiel 24105, Germany. Electronic address: .
Grenkowitz T; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany.
Ruidavets JB; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1027, Toulouse, France.
Kassner U; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany.
Duparc T; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France.
Combes G; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France.
Perret B; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France.
Genoux A; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France.
Schumann F; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany.
Bobbert T; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany.
Steinhagen-Thiessen E; Department of Endocrinology, Division of Lipid Disorders, Charité Universitätsmedizin Berlin, Berlin, Germany.
Martinez LO; Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France.
Pokaż więcej
Źródło :
Vascular pharmacology [Vascul Pharmacol] 2020 Dec; Vol. 135, pp. 106804. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anticholesteremic Agents/*therapeutic use
Atherosclerosis/*prevention & control
Cholesterol, HDL/*blood
Dyslipidemias/*drug therapy
Proprotein Convertase 9/*antagonists & inhibitors
Serine Proteinase Inhibitors/*therapeutic use
Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Anticholesteremic Agents/adverse effects ; Atherosclerosis/blood ; Atherosclerosis/etiology ; Biomarkers/blood ; Drug Therapy, Combination ; Dyslipidemias/blood ; Dyslipidemias/complications ; Ezetimibe/therapeutic use ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Magnetic Resonance Spectroscopy ; Male ; Middle Aged ; Particle Size ; Risk Assessment ; Risk Factors ; Serine Proteinase Inhibitors/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Hyperlipidemia management in Slovakia: observational study.
Autorzy :
Fábryová U
Nemcová A
Pokaż więcej
Transliterated Title :
Manažment hyperlipidémie na Slovensku: observačná štúdia.
Źródło :
Vnitrni lekarstvi [Vnitr Lek] 2020 Winter; Vol. 65 (12), pp. 761-769.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anticholesteremic Agents*/therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Hyperlipidemias*/drug therapy
Adult ; Europe, Eastern ; Humans ; Retrospective Studies ; Slovakia ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis.
Autorzy :
Arashi H; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Yamaguchi J; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Kawada-Watanabe E; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Otsuki H; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Sekiguchi H; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Ogawa H; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Hagiwara N; Department of Cardiology, The Heart Institute of Japan, 13131Tokyo Women's Medical University, Tokyo, Japan.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2020 Nov; Vol. 25 (6), pp. 548-555. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acute Coronary Syndrome/*drug therapy
Anticholesteremic Agents/*therapeutic use
Arachidonic Acid/*blood
Eicosapentaenoic Acid/*blood
Ezetimibe/*therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Quinolines/*therapeutic use
Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/diagnosis ; Aged ; Anticholesteremic Agents/adverse effects ; Biomarkers/blood ; Ezetimibe/adverse effects ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Japan ; Male ; Middle Aged ; Multicenter Studies as Topic ; Quinolines/adverse effects ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Hypercholesterolemia - the way to lower LDL-C < 55 mg/dl].
Autorzy :
Vogt A; Med. Klinik u. Poliklinik IV\/Stoffwechselambulanz, Ziemssenstraße 1, 80336, München, Germany. .
Pokaż więcej
Transliterated Title :
Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Źródło :
MMW Fortschritte der Medizin [MMW Fortschr Med] 2020 Nov; Vol. 162 (Suppl 3), pp. 36-42.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents*/therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Hypercholesterolemia*/diagnosis
Hypercholesterolemia*/drug therapy
Hyperlipidemias*
Cholesterol, LDL ; Humans
Czasopismo naukowe
Tytuł :
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
Autorzy :
Robinson JG; Division of Cardiology, Department of Epidemiology and Internal Medicine, University of Iowa, Iowa City, IA, United States of America.
Jayanna MB; Division of Cardiovascular Disease, Department of Medicine, Lenkenau Medical Center & Lankenau Institute for Medical Research, Wynnewood, PA, United States of America.
Bairey Merz CN; Barbara Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, United States of America.
Stone NJ; Bluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Oct 29; Vol. 15 (10), pp. e0240166. Date of Electronic Publication: 2020 Oct 29 (Print Publication: 2020).
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Anticholesteremic Agents/*therapeutic use
Atorvastatin/*therapeutic use
Coronary Artery Disease/*drug therapy
Ezetimibe/*therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Antibodies, Monoclonal, Humanized/administration & dosage ; Anticholesteremic Agents/administration & dosage ; Atorvastatin/administration & dosage ; Clinical Trials as Topic ; Coronary Artery Disease/epidemiology ; Drug Utilization/statistics & numerical data ; Ezetimibe/administration & dosage ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
Czasopismo naukowe
Tytuł :
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Autorzy :
Kitagawa K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Moriya K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Kaji K; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Saikawa S; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Sato S; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Nishimura N; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Namisaki T; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Akahane T; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Mitoro A; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Yoshiji H; Department of Gastroenterology and Hepatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 14; Vol. 21 (20). Date of Electronic Publication: 2020 Oct 14.
Typ publikacji :
Journal Article
MeSH Terms :
Anticholesteremic Agents/*pharmacology
Antimetabolites, Antineoplastic/*pharmacology
Atorvastatin/*pharmacology
Bile Duct Neoplasms/*drug therapy
Cholangiocarcinoma/*drug therapy
Deoxycytidine/*analogs & derivatives
Proto-Oncogene Proteins c-yes/*metabolism
Animals ; Anticholesteremic Agents/administration & dosage ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Apoptosis/drug effects ; Atorvastatin/administration & dosage ; Bile Duct Neoplasms/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cholangiocarcinoma/metabolism ; Connective Tissue Growth Factor/genetics ; Connective Tissue Growth Factor/metabolism ; Contractile Proteins/genetics ; Contractile Proteins/metabolism ; Cysteine-Rich Protein 61/genetics ; Cysteine-Rich Protein 61/metabolism ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Combinations ; Drug Interactions ; Humans ; Intercellular Signaling Peptides and Proteins/genetics ; Intercellular Signaling Peptides and Proteins/metabolism ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Muscle Proteins/genetics ; Muscle Proteins/metabolism ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Repressor Proteins/genetics ; Repressor Proteins/metabolism
Czasopismo naukowe
Tytuł :
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
Autorzy :
Duprez DA; Cardiovascular Division, School of Medicine, University of Minnesota, Minneapolis, MN, USA.
Handelsman Y; Metabolic Institute of America, Tarzana, CA, USA.
Koren M; Jacksonville Center for Clinical Research, Jacksonville, FL, USA.
Pokaż więcej
Źródło :
Vascular health and risk management [Vasc Health Risk Manag] 2020 Oct 07; Vol. 16, pp. 403-418. Date of Electronic Publication: 2020 Oct 07 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticholesteremic Agents/*therapeutic use
Cardiovascular Diseases/*prevention & control
Cholesterol, LDL/*blood
Dyslipidemias/*drug therapy
Proprotein Convertase 9/*antagonists & inhibitors
Serine Proteinase Inhibitors/*therapeutic use
Anticholesteremic Agents/adverse effects ; Biomarkers/blood ; Cardiovascular Diseases/epidemiology ; Drug Therapy, Combination ; Dyslipidemias/blood ; Dyslipidemias/epidemiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Risk Factors ; Serine Proteinase Inhibitors/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
HDL (High-Density Lipoprotein) Remodeling and Magnetic Resonance Imaging-Assessed Atherosclerotic Plaque Burden: Study in a Preclinical Experimental Model.
Autorzy :
Ben-Aicha S; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).; School of Medicine, University of Barcelona (UB), Spain (S.B., G.M.).
Casaní L; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).
Muñoz-García N; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).
Joan-Babot O; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).
Peña E; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV) Instituto de Salud Carlos III (T.P., L.B., G.V., E.P.).
Aržanauskaitė M; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).
Gutierrez M; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).
Mendieta G; School of Medicine, University of Barcelona (UB), Spain (S.B., G.M.).; Cardiology Department, Hospital Clinico Barcelona Spain (G.M.).
Padró T; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV) Instituto de Salud Carlos III (T.P., L.B., G.V., E.P.).
Badimon L; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV) Instituto de Salud Carlos III (T.P., L.B., G.V., E.P.).; Cardiovascular Research Chair, Universidad Autónoma Barcelona (UAB), Spain(L.B.).
Vilahur G; Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain (S.B., L.C., N.M.-G., O.J.-B., E.P., M.A., M.G., T.P., L.B., G.V.).; Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV) Instituto de Salud Carlos III (T.P., L.B., G.V., E.P.).
Pokaż więcej
Źródło :
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2020 Oct; Vol. 40 (10), pp. 2481-2493. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Magnetic Resonance Imaging*
Plaque, Atherosclerotic*
Anticholesteremic Agents/*administration & dosage
Aorta, Abdominal/*drug effects
Aortic Diseases/*prevention & control
Atherosclerosis/*prevention & control
Cholesterol, HDL/*administration & dosage
Hypercholesterolemia/*drug therapy
Animals ; Anticholesteremic Agents/toxicity ; Aorta, Abdominal/diagnostic imaging ; Aorta, Abdominal/metabolism ; Aortic Diseases/blood ; Aortic Diseases/diagnostic imaging ; Aortic Diseases/etiology ; Atherosclerosis/blood ; Atherosclerosis/diagnostic imaging ; Atherosclerosis/etiology ; Biomarkers/blood ; Cholesterol, HDL/blood ; Cholesterol, HDL/toxicity ; Disease Models, Animal ; Disease Progression ; Hypercholesterolemia/blood ; Hypercholesterolemia/complications ; Infusions, Intravenous ; Male ; Rabbits
Czasopismo naukowe
Tytuł :
Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
Autorzy :
Hovland A; Coronary Care Unit, Division of Internal Medicine, Nordland Hospital, Bodø, Norway.; Department of Clinical Medicine, University of Tromsø, Tromsø, Norway.
Retterstøl K; The Lipid Clinic, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Nutrition, University of Oslo, Oslo, Norway.
Mollnes TE; Department of Clinical Medicine, University of Tromsø, Tromsø, Norway.; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.; Research Laboratory, Nordland Hospital, Bodø, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Institute of Immunology, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
Halvorsen B; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
Aukrust P; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Lappegård KT; Coronary Care Unit, Division of Internal Medicine, Nordland Hospital, Bodø, Norway.; Department of Clinical Medicine, University of Tromsø, Tromsø, Norway.
Pokaż więcej
Źródło :
Scandinavian cardiovascular journal : SCJ [Scand Cardiovasc J] 2020 Oct; Vol. 54 (5), pp. 274-279. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Anticholesteremic Agents/*therapeutic use
Atherosclerosis/*drug therapy
Cholesterol, LDL/*blood
Inflammation/*drug therapy
Inflammation Mediators/*blood
Animals ; Anti-Inflammatory Agents/adverse effects ; Anticholesteremic Agents/adverse effects ; Atherosclerosis/blood ; Atherosclerosis/diagnosis ; Biomarkers/blood ; Down-Regulation ; Humans ; Inflammation/blood ; Inflammation/diagnosis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies